DK1414496T3 - Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid - Google Patents
Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glyceridInfo
- Publication number
- DK1414496T3 DK1414496T3 DK02766983.7T DK02766983T DK1414496T3 DK 1414496 T3 DK1414496 T3 DK 1414496T3 DK 02766983 T DK02766983 T DK 02766983T DK 1414496 T3 DK1414496 T3 DK 1414496T3
- Authority
- DK
- Denmark
- Prior art keywords
- pravastatin
- pharmaceutical composition
- ppar
- alpha
- combination
- Prior art date
Links
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960002965 pravastatin Drugs 0.000 title abstract 2
- 102000023984 PPAR alpha Human genes 0.000 title 1
- 125000005456 glyceride group Chemical group 0.000 title 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 title 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 title 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 229960000701 fenofibric acid Drugs 0.000 abstract 1
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 abstract 1
- 229940074796 pravastatin and fenofibrate Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE0100133 | 2001-08-07 | ||
| PCT/BE2001/000147 WO2003013607A1 (en) | 2001-08-07 | 2001-09-07 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR |
| PCT/BE2002/000135 WO2003013608A1 (en) | 2001-08-07 | 2002-08-07 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1414496T3 true DK1414496T3 (da) | 2011-01-24 |
Family
ID=3862570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02766983.7T DK1414496T3 (da) | 2001-08-07 | 2002-08-07 | Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20070092567A1 (da) |
| AT (2) | ATE322896T1 (da) |
| DE (1) | DE60238059D1 (da) |
| DK (1) | DK1414496T3 (da) |
| ES (1) | ES2352189T3 (da) |
| PT (1) | PT1414496E (da) |
| WO (2) | WO2003013607A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534660A1 (en) * | 2003-08-05 | 2005-02-10 | Galephar M/F | Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
| WO2005013940A1 (en) * | 2003-08-06 | 2005-02-17 | Galephar M/F | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin |
| CN103040798A (zh) * | 2011-11-08 | 2013-04-17 | 深圳信立泰药业股份有限公司 | 一种苯扎贝特缓释药物组合物 |
| ES2717470T3 (es) | 2011-12-14 | 2019-06-21 | Lts Lohmann Therapie Systeme Ag | Formulaciones de obleas y cápsulas con velocidades de disolución aumentadas para fenofibrato |
| KR102501636B1 (ko) * | 2021-12-07 | 2023-02-21 | 에이스바이오팜 주식회사 | 페노피브린산을 포함하는 경구용 정제 및 이의 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2039763A1 (en) * | 1990-04-30 | 1991-10-31 | Henry Y. Pan | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination |
| CA2048395A1 (en) * | 1990-08-23 | 1992-02-24 | Henry Y. Pan | Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin |
| BE1011363A3 (fr) * | 1997-09-11 | 1999-08-03 | Smb Technology | Capsules semi-solides autoemulsionnables matricielles a action prolongee. |
| DE19858789A1 (de) * | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6368620B2 (en) * | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| KR100801588B1 (ko) * | 1999-09-21 | 2008-02-05 | 스키에파마 캐나다 인코포레이티드 | 생물학적 유효 물질의 표면 변형된 미립자 조성물 |
| US6531507B1 (en) * | 2000-06-09 | 2003-03-11 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| EP1361867B1 (en) * | 2001-02-22 | 2007-03-21 | Jagotec AG | Fibrate-statin combinations with reduced fed-fasted effects |
| US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
-
2001
- 2001-09-07 WO PCT/BE2001/000147 patent/WO2003013607A1/en unknown
-
2002
- 2002-04-05 WO PCT/BE2002/000051 patent/WO2003013501A1/en not_active Application Discontinuation
- 2002-07-17 AT AT02748487T patent/ATE322896T1/de not_active IP Right Cessation
- 2002-08-07 PT PT02766983T patent/PT1414496E/pt unknown
- 2002-08-07 DK DK02766983.7T patent/DK1414496T3/da active
- 2002-08-07 DE DE60238059T patent/DE60238059D1/de not_active Expired - Lifetime
- 2002-08-07 AT AT02766983T patent/ATE485058T1/de active
- 2002-08-07 ES ES02766983T patent/ES2352189T3/es not_active Expired - Lifetime
-
2006
- 2006-02-06 US US11/347,822 patent/US20070092567A1/en not_active Abandoned
-
2010
- 2010-07-07 US US12/805,021 patent/US20150037414A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1414496E (pt) | 2012-04-20 |
| WO2003013501A1 (en) | 2003-02-20 |
| ATE485058T1 (de) | 2010-11-15 |
| ATE322896T1 (de) | 2006-04-15 |
| US20150037414A1 (en) | 2015-02-05 |
| DE60238059D1 (de) | 2010-12-02 |
| WO2003013607A1 (en) | 2003-02-20 |
| ES2352189T3 (es) | 2011-02-16 |
| US20070092567A1 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60127457D1 (de) | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen | |
| PT797991E (pt) | Formulacao com libertacao prolongada contendo venlafaxina | |
| MX9204268A (es) | Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma. | |
| ATE223207T1 (de) | Tablette mit instant- und verzögerte freisetzung von einen oder mehrere wirkstoffe | |
| ID30205A (id) | Asam-asam lemak esensial dalam pencegahan kejadian-kejadian kardiovaskular | |
| ATE386508T1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
| DE69720787D1 (de) | Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure | |
| DK0656776T3 (da) | Flerlagstabletter med reguleret frigivelse indeholdende både naproxen og naproxen-natriumsalt | |
| FI973828A (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
| IS2749B (is) | Ný tegund af lyfjablöndu | |
| IT8423086A1 (it) | Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica | |
| ATE317280T1 (de) | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung | |
| DE60008127D1 (de) | Diät mit hohem lipidgehalt | |
| BRPI0412697A (pt) | composições farmacêuticas que apresentam um revestimento expansìvel | |
| NZ522242A (en) | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
| DK1651194T3 (da) | Stabile farmaceutiske sammensætninger med kontrolleret frigivelse, hvilke indeholder fenofibrat og pravastatin | |
| DK1414496T3 (da) | Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid | |
| JP2002536304A5 (da) | ||
| NO996468D0 (no) | Anvendelse av gaba-analoger slik som gabapentin i fremstillingen av et medikament for behandling av betennelsessykdommer | |
| DK0667155T3 (da) | Tabletter med thioctsyre med bestemt kornstørrelse | |
| ITRM920222A0 (it) | Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari. | |
| ATE258435T1 (de) | Pinolensäure gegen diabetes | |
| ATE199495T1 (de) | Pharmazeutische zubereitung zur direktverpressung | |
| DK1062954T3 (da) | Anvendelse af itakonsyre til regulering af det glykotiske stofskifte | |
| ES2082523T3 (es) | Un medicamento de accion retardada que contiene ibuprofen y su empleo. |